A
Angie A. Kehagia
Researcher at King's College London
Publications - 19
Citations - 1956
Angie A. Kehagia is an academic researcher from King's College London. The author has contributed to research in topics: Parkinson's disease & Prefrontal cortex. The author has an hindex of 12, co-authored 18 publications receiving 1720 citations. Previous affiliations of Angie A. Kehagia include University of Cambridge & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
TL;DR: Remediation and management prospects for cognitive deficits in patients with Parkinson's disease are based on neuropharmacological and cognitive rehabilitation approaches, supplemented by advances in neuroimaging and genetic research.
Journal ArticleDOI
Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis.
TL;DR: The dual syndrome hypothesis is distinguished, which distinguishes between dopaminergically mediated fronto-striatal executive impairments and a dementia syndrome with distinctive prodromal visuospatial deficits in which cholinergic treatments offer some clinical benefits.
Journal ArticleDOI
Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation
TL;DR: The role of prefrontal noradrenaline (NA) in higher order flexibility indexed through attentional set-shifting has recently received significant empirical support, and similar avenues appear promising in the field of task switching.
Journal ArticleDOI
Targeting impulsivity in Parkinson’s disease using atomoxetine
Angie A. Kehagia,Charlotte R. Housden,Ralf Regenthal,Roger A. Barker,Ulrich Müller,James H. Rowe,Barbara J. Sahakian,Trevor W. Robbins +7 more
TL;DR: Consistent with the presence of a longstanding noradrenergic deficit, atomoxetine improved stopping accuracy, and reduced reflection impulsivity during decision making in patients with Parkinson’s disease.
Journal ArticleDOI
Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication
Juha Veijola,Joyce Y. Guo,Jani Moilanen,Erika Jääskeläinen,Jouko Miettunen,Merja Kyllönen,Marianne Haapea,Sanna Huhtaniska,Antti Alaräisänen,Pirjo Mäki,Vesa Kiviniemi,Juha Nikkinen,Tuomo Starck,Jukka Remes,Päivikki Tanskanen,Osmo Tervonen,Alle Meije Wink,Angie A. Kehagia,John Suckling,Hiroyuki Kobayashi,Jennifer H. Barnett,Anna Barnes,Hannu Koponen,Peter B. Jones,Matti Isohanni,Graham K. Murray +25 more
TL;DR: In this population based sample, brain volume reduction continues in schizophrenia patients after the onset of illness, and antipsychotic medications may contribute to these reductions.